Title : Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Pub. Date : 2019 Jun

PMID : 30317534






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Introduction Selumetinib (AZD6244, ARRY-142886) is a potent inhibitor of MEK1/2, thereby inhibiting phosphorylation of ERK2. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens
2 Introduction Selumetinib (AZD6244, ARRY-142886) is a potent inhibitor of MEK1/2, thereby inhibiting phosphorylation of ERK2. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens
3 Introduction Selumetinib (AZD6244, ARRY-142886) is a potent inhibitor of MEK1/2, thereby inhibiting phosphorylation of ERK2. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens